Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entity

por Calabrese, C, Kirchner, E, Kontzias, K, Velcheti, V, Calabrese, L H
Publicado 2017

Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States

por Jain, P., Gutierrez Bugarin, J., Guha, A., Jain, C., Patil, N., Shen, T., Stanevich, I., Nikore, V., Margolin, K., Ernstoff, M., Velcheti, V., Barnholtz-Sloan, J., Dowlati, A.
Publicado 2021

Selective RET kinase inhibition for patients with RET-altered cancers

por Subbiah, V, Velcheti, V, Tuch, B B, Ebata, K, Busaidy, N L, Cabanillas, M E, Wirth, L J, Stock, S, Smith, S, Lauriault, V, Corsi-Travali, S, Henry, D, Burkard, M, Hamor, R, Bouhana, K, Winski, S, Wallace, R D, Hartley, D, Rhodes, S, Reddy, M, Brandhuber, B J, Andrews, S, Rothenberg, S M, Drilon, A
Publicado 2018